Experimental LSD Treatment Shows Promise for Generalized Anxiety Disorder
A pharmaceutical formulation of LSD, known as MM120, is demonstrating significant potential in alleviating symptoms of generalized anxiety disorder (GAD) in a clinical trial led by researchers at UCSF.
Generalized anxiety disorder affects approximately one in 20 U.S. adults, often leading to debilitating symptoms like difficulty concentrating, insomnia, and social isolation. Current treatments, such as Zoloft and Paxil, typically offer limited relief, reducing anxiety scale scores by an average of only 1.25 points on a 56-point scale. However, preliminary results from a study published in JAMA indicate that MM120 reduced symptoms by five to six points, enough to reclassify moderate GAD as mild in some patients. “LSD as well as other psychedelics, have tremendous potential to shift mood and emotions when used in a controlled, therapeutic setting,” explained UCSF neuroscientist Jennifer Mitchell, PhD.
The trial, involving approximately 200 participants with moderate-to-severe GAD, found that MM120 promotes neuroplasticity in the brain, potentially altering negative thought patterns and improving communication between brain regions. While participants experienced mild to moderate side effects, including hallucinations, visual distortions, nausea, and headache, these were manageable with proactive anti-nausea medication and were more prevalent at the highest dosage – which researchers have since determined is no more effective. Finding eligible participants has proven challenging, as those most severely affected are often the least likely to seek treatment; researchers are relying on skilled clinicians to build trust and encourage participation in the study. More information about UCSF’s research can be found on their website.
Researchers are continuing to recruit participants for ongoing trials at UCSF and other California locations, hoping to further validate these promising results and potentially offer a new treatment option for those struggling with GAD. The success of this trial could represent a paradigm shift in how anxiety disorders are treated, offering hope to millions who don’t respond to conventional therapies.
